EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy

R Sharon Chinthrajah iD, Sayantani B Sindher, Kari C Nadeau iD, Jeffrey G Leflein, Jonathan M Spergel, Daniel H Petroni, Stacie M Jones, Thomas B Casale, Julie Wang, Warner W Carr, Wayne G Shreffler, Robert A Wood und 14 weitere

Allergy · 2025-03 · 80 (3) · 827-842

DOI: 10.1111/all.16420 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 14.12.2024. Verfasst von R Sharon Chinthrajah und 25 weiteren Autor:innen. Beteiligte Einrichtung: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Antibodies, Monoclonal, Humanized, Desensitization, Immunologic. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi and Regeneron Pharmaceuticals Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peanut allergy is a common, life‐threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)‐4/IL‐13, enhances the efficacy of oral immunotherapy (OIT) AR101 in pediatric patients with peanut allergy.

Methods

A Phase II, multicenter, randomized, double‐blind study was conducted in the USA (NCT03682770) in pediatric patients (6–≤ 17 years old) with confirmed peanut allergy. Patients were randomized 2:1 to receive dupilumab + OIT or placebo + OIT during a 28–40‐week up‐dosing period. Patients in the dupilumab + OIT group were re‐randomized 1:1 and received dupilumab + OIT or placebo + OIT during 24‐week OIT maintenance, undergoing a 2044 mg (cumulative) of peanut protein double‐blind, placebo‐controlled food challenge (DBPCFC) following up‐dosing, maintenance, and at 12‐week post‐treatment follow‐up.

Results

The study enrolled 148 patients, 123 of whom were included in the modified full analysis set, with a mean age of 11.1 years. Dupilumab + OIT treatment ( n = 84) led to a 20.2% increase ( p < 0.05) in the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein following the up‐dosing period versus placebo (OIT alone, n = 39). Following the OIT maintenance period, continuous dupilumab treatment improved the number of patients who passed a DBPCFC to 2044 mg (cumulative) of peanut protein versus patients continuously on OIT alone (16.6% difference [95% CI −9.7, 42.8], p = 0.2123). Safety was consistent with known dupilumab safety profile.

Conclusions

Dupilumab provided a modest increase efficacy of OIT in children and adolescents with peanut allergy, though it did not provide protection against OIT‐related anaphylaxis. Trial Registration ClinicalTrials.gov identifier: NCT03793608

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityAntibodies, Monoclonal, HumanizedDesensitization, ImmunologicHumansChildMaleFemaleAdolescentAdministration, OralTreatment OutcomeDouble-Blind MethodAllergensImmunoglobulin E

Stichwörter der Autor:innen

OITchildrendupilumabpeanut allergy

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabAllergensImmunoglobulin E

Autor:innen und Institutionen

  • Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.
  • Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
  • Allergy & Immunology Association of Michigan, Ypsilanti, Michigan, USA.
  • Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Seattle Allergy & Asthma Research Institute, Seattle, Washington, USA.
  • Department of Pediatrics, Division of Allergy and Immunology, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas, USA.

ORCID-Profile: R Sharon Chinthrajah, Kari C Nadeau, Erik Wambre, Jamie M Orengo, Jennifer D Hamilton

Förderung

  • Sanofi and Regeneron Pharmaceuticals Inc.

Zitieren

APA

Chinthrajah, R. S., Sindher, S. B., Nadeau, K. C., Leflein, J. G., Spergel, J. M., Petroni, D. H., Jones, S. M., Casale, T. B., Wang, J., Carr, W. W., Shreffler, W. G., Wood, R. A., Wambre, E., Liu, J., Akinlade, B., Atanasio, A., Orengo, J. M., Hamilton, J. D., Kamal, M. A., …, & Radin, A. R. (2025). Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy. Allergy, 80(3), 827-842. https://doi.org/10.1111/all.16420

Vancouver

Chinthrajah RS, Sindher SB, Nadeau KC, Leflein JG, Spergel JM, Petroni DH, et al. Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy. Allergy. 2025;80(3):827-842. doi:10.1111/all.16420

BibTeX
@article{Chinthrajah2025,
  author = {Chinthrajah, R Sharon and Sindher, Sayantani B and Nadeau, Kari C and Leflein, Jeffrey G and Spergel, Jonathan M and Petroni, Daniel H and Jones, Stacie M and Casale, Thomas B and Wang, Julie and Carr, Warner W and Shreffler, Wayne G and Wood, Robert A and Wambre, Erik and Liu, Jinzhong and Akinlade, Bolanle and Atanasio, Amanda and Orengo, Jamie M and Hamilton, Jennifer D and Kamal, Mohamed A and Hooper, Andrea T and Patel, Kiran and Laws, Elizabeth and Mannent, Leda P and Adelman, Daniel C and Ratnayake, Anoshie and Radin, Allen R},
  title = {Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {3},
  pages = {827--842},
  doi = {10.1111/all.16420}
}
Kostenlos starten →